那么，华润究竟是如何深入我们的日常生活的呢？ 华润的强大，首先体现在其庞大的上市公司矩阵。你或许难以置信，它旗下拥有多达18家上市公司，A股、港股各占9席，横跨消费、健康、地产、能源、 科技等六大核心赛道，构建了一个多元化的商业帝国。2023年，华润在《财富》世界500强中位列第67位，实力可见一斑。仅2023年前三季度，其营收就高 达6514亿元，利润总额达到643亿元，增幅均超过央企平均水平，展现出强劲的盈利能力。 作为中国四大央企之一，华润集团的实力远超人们的传统印象。它不仅是"卖啤酒、开商场"的，更是一个渗透到我们生活方方面面的"隐形大佬"。你可能每 天都在和它旗下的品牌打交道：夏天撸串时畅饮的雪花啤酒，感冒时冲服的999感冒灵，周末在万象城享受的购物体验，家中烹饪使用的管道燃气，甚至长 辈们滋补身体的东阿阿胶——这些国民品牌，都与华润有着千丝万缕的联系。 在大健康板块，除了我们熟知的OTC药品，华润医药是医药分销行业的前三强，而华润医疗则运营着146家医疗机构，其中包括13家三甲医院，提供2.1万张 床位。华润医疗实现了从药材种植到终端医疗服务的全链条覆盖，构建了完善的医疗健康生态。 华润的多元化布 ...

与此同时，华润三九总部品牌市集同步开启，以"六大特色摊位+沉浸式体验"为核心亮点，打造了一场 集品牌展示、文化传承与互动乐趣于一体的健康盛会。不同于集团市集的综合展示，总部市集更侧重深 度体验与媒体嘉宾及周边社群的情感联结，六大摊位各有特色：昆药集团摊位将非遗漆扇制作与医药产 品展示相结合，让匠心工艺与健康理念碰撞融合；天士力集团"拓古印今，药启新章"摊位通过非遗拓印 体验，传递传统文化与现代医药的创新融合魅力；本草悟品牌摊位带来治愈系香囊DIY体验，专属养生 茶系列与膳·颐膳系列汤品，让草本养生融入日常生活；三九胃泰摊位的肠胃迷宫挑战，将胃肠养护知 识融入趣味游戏，通关即可领取奖品，兼具娱乐性与科普性；天和品牌摊位的"投掷沙包击中痛点"互 动，让观众在轻松氛围中了解关节健康知识，感受经典贴膏产品的守护价值；华润堂摊位则推出系列产 品内购优惠，以实惠价格让大家收获优质健康好物。 值得一提的是，市集全场贯穿"三舅"IP福利主线，观众参与任意摊位互动后，扫码添加"三舅"企业微信 好友即可参与现场活动领取定制奖品，进一步强化了品牌记忆点。活动现场，专业工作人员全程为参与 12月17至18日，在华润集团品牌日系列活动 ...

同时，京东买药秒送还倡导骑手在送货前后严格做好自身安全消杀，全程规范佩戴口罩，以标准化防护 措施守护自身健康，也为配送全流程安全加码。京东买药秒送将面向骑手，定期推送流感防治、日常保 健、防护技巧等健康知识，提升骑手自我健康管理意识与防护能力。 京东买药秒送的"流感季骑手护航计划"，是出于对骑手群体健康安全的切实关怀，而落点则是对配送安 全与用户健康的双重责任。通过筑牢配送"最后一公里"的安全防线，让每一份药品在送达过程中多一重 防护、多一份安心，为用户提供一份全程可控的安心保障。这个流感季，京东买药秒送以扎实行动， 让"放心买药、安心送达"成为可以感知的服务温度。 本报讯(记者袁传玺)近日，全国流感进入高流行水平，药品即时配送需求激增。穿梭于城市中的骑手成 为连接健康与急需的关键纽带。而频繁接触各类环境与人群，也让他们的健康防护面临考验。保障骑手 健康，不仅是对劳动者的关怀，更是确保药品安全配送、让用户安心买药的重要基础。为此，京东买药 秒送正式推出"流感季骑手护航计划"，以多维度举措为骑手与用户双向护航，用户在流感季买药更放 心、更安心。 此次推出的"流感季骑手护航计划"重点围绕物资保障与规范管理两大维度 ...

近日，全国流感进入高流行水平，药品即时配送需求激增。穿梭于城市中的骑手成为连接健康与急需的 关键纽带。而频繁接触各类环境与人群，也让他们的健康防护面临考验。保障骑手健康，不仅是对劳动 者的关怀，更是确保药品安全配送、让用户安心买药的重要基础。为此，京东买药秒送正式推出"流感 季骑手护航计划"，以多维度举措为骑手与用户双向护航，用户在流感季买药更放心、更安心。 此次推出的"流感季骑手护航计划"重点围绕物资保障与规范管理两大维度展开。京东买药秒送联合 999、海氏海诺等品牌，将面向所有骑手免费提供流感防护物资，包括消毒湿巾、口罩、999感冒灵、消 毒水等实用防护及应急物资，精准解决流感季骑手出行防护需求。同时，鼓励骑手将流感防护物资中的 口罩等物资作为应急共享资源，若遇路人有紧急防护需求，可酌情提供帮助，传递配送途中的健康守护 温度。 同时，京东买药秒送还倡导骑手在送货前后严格做好自身安全消杀，全程规范佩戴口罩，以标准化防护 措施守护自身健康，也为配送全流程安全加码。京东买药秒送将面向骑手，定期推送流感防治、日常保 健、防护技巧等健康知识，提升骑手自我健康管理意识与防护能力。 京东买药秒送的"流感季骑手护航计划" ...

◎记者黎灵希 "999感冒灵，暖暖的，很贴心。"这句家喻户晓的广告词，成就了"999"的医药健康品牌，也成为它守护 无数家庭日常健康的朴素情怀。华润三九由此出发，搭建了横跨全生命周期、纵贯全健康管理场景 的"1+N"品牌矩阵。 华润三九从靠几款OTC药品打开市场的企业，蜕变为中国医药行业的"多面手"——连续多年位列非处方 药生产企业综合排名榜首，在处方药领域构建了中药、化药、生物药协同发展的创新格局。 近日，上海证券报记者走进华润三九，探寻这家国民药企打通高质量发展"任督二脉"的故事。 "'十四五'期间，我们积极抓住行业和市场机遇，提前完成营收翻番的目标。"华润三九董事长邱华伟告 诉记者，"下一个五年，公司的自主研发能力及管线将呈现更强大的活力。" 引擎："创新+品牌"双轮驱动 2024年实现营收276亿元，较2020年增长超102%；近三年营收、利润总额年复合增长率分别达23.6%、 24.5%……采访伊始，邱华伟用一组关键数据开启了对话。 "公司一方面持续打造具有疗效优势、品质感强的差异化产品矩阵，另一方面通过和消费者保持长期沟 通，不断延伸品牌效应。"邱华伟说，公司始终贴近消费者的沟通语境，持续探索媒介 ...

Group 1 - Dongyangguang Pharmaceutical's total revenue from 2022 to 2024 is projected to reach 14.2 billion, with R&D investment of 2.5 billion over the past three years, and operating profit exceeding 2.1 billion in the last two years [21] - Huaren Sanjiu's R&D investment is expected to reach 950 million in 2024, a 63.97% increase from 2020, with R&D personnel increasing to 876, more than double that of 2020 [21] - Yunnan Baiyao achieved a net profit of 4.777 billion in the first three quarters of 2025, a year-on-year increase of 10.41%, surpassing the full-year profit of 4.749 billion in 2024, marking a historical high for the same period [21] Group 2 - Yunnan Baiyao emphasizes the importance of returning to its core business and focusing on continuous effective R&D investment to build a competitive moat [22] - Huaren Sanjiu is accelerating its merger and integration pace, focusing on consumer health, medical health, and elderly health sectors, while enhancing R&D investment to drive innovation transformation [22] - Dongyangguang Pharmaceutical has developed three self-researched new drugs and has nearly 50 new drugs in the pipeline, actively seeking international markets for growth [26][31] Group 3 - Yanhuilong has invested over 1 billion in R&D from 2021 to 2024, with annual R&D investment accounting for over 20% of its main business revenue [21][51] - The company is shifting from rapid market capture to deep innovation, focusing on high-quality development and establishing a unique project advantage in the IVD industry [49][50] - Yanhuilong's overseas revenue exceeded 200 million in the first three quarters, a nearly 40% year-on-year increase, indicating successful market expansion [54] Group 4 - Yunnan Baiyao's revenue has grown from 58 million to 40.033 billion over 32 years, a 690-fold increase, with net profit rising from 1.3 million to 4.749 billion, a 365-fold increase [40] - The company has established a digital transformation strategy, creating a full-chain digital system to enhance operational efficiency and product quality [41][42] - Yunnan Baiyao's strategic planning includes three R&D curves focusing on traditional Chinese medicine, innovative drugs, and nuclear medicine [48] Group 5 - Dongyangguang Pharmaceutical has built a comprehensive R&D system and a modern factory with an annual production capacity of 1.8 billion tablets [29] - The company is actively integrating AI into drug discovery processes to enhance efficiency and reduce costs [30] - Huaren Sanjiu's revenue is projected to reach 27.6 billion in 2024, a 102% increase from 2020, with a compound annual growth rate of 23.6% in revenue and 24.5% in profit over the past three years [35]

在信息过载的数字化时代，品牌与用户的有效沟通成为核心竞争力。近日，全球品牌网总编辑、京津冀融媒体中心主任刘月好基于多年品牌传播实战经验， 提出"内容黄金三角"核心原则——价值感、传播性、场景化，为企业破解内容同质化、传播低效等痛点提供实操路径，引发行业广泛关注。 刘月好强调，优质内容是品牌与用户对话的核心载体，而"内容黄金三角"的三个维度相互支撑、缺一不可。价值感是根基，需打造用户不可或缺的稀缺认 知。他指出，价值感并非单纯的功能介绍，而是精准击中用户痛点的解决方案或情感满足。老铺黄金便是典型案例，其摒弃黄金行业"按克计价"的同质化竞 争，通过非遗古法工艺与传统文化叙事，将产品升维为"可佩戴的家族传承"，凭借文化价值感实现克价超同行60%仍逆势增长，2024年净利润暴增近 200%。"价值感的核心是在用户心智中建立稀缺性，让内容成为用户愿意主动关注的'刚需品'"，刘月好补充道。 传播性是放大器，要激活用户自发分享的 裂变势能。刘月好认为，传播性的关键在于情感共鸣与互动设计，而非硬广式灌输。999感冒灵的抖音挑战赛堪称典范，品牌围绕"多喝热水变装"等年轻化 话题，打造强互动内容，吸引黄明昊等明星及千万级达人自发 ...

Group 1: Fixed Income - The manufacturing PMI for November shows a slowdown in contraction, with the index rising to 49.2%, an increase of 0.2 percentage points from the previous month, indicating a slight improvement in production and demand [7][8] - The non-manufacturing business activity index fell to 49.5%, a decrease of 0.6 percentage points, suggesting that the service sector has entered a contraction phase [7][11] - The construction industry has remained below the growth line for four consecutive months, necessitating further economic stabilization policies [7][11] Group 2: Real Estate - The sales revenue of the top 100 real estate companies in November decreased by 36.8% year-on-year and 11.7% month-on-month, indicating a significant decline as the market enters a sales lull [14][15] - The sales area for the top 100 companies also saw a year-on-year decline of 35.8%, although the rate of decline has lessened compared to previous months [14][15] - There is an increasing expectation for policy easing as the market shows signs of weakness, suggesting potential investment opportunities in the sector [14][16] Group 3: Pharmaceutical and Biotechnology - The company Huaren Sanjiu (000999.SZ) reported a revenue of 21.986 billion yuan for the first three quarters, a year-on-year increase of 11.38%, with a net profit of 2.353 billion yuan, reflecting a decline of 20.51% [18][19] - The company is focusing on both internal and external growth strategies, particularly in the consumer health sector, and is expected to achieve net profits of 3.295 billion yuan, 3.843 billion yuan, and 4.268 billion yuan for 2025, 2026, and 2027 respectively [19][20] - The company has a strong brand value and advantages in traditional Chinese medicine, which supports its growth potential [19][20] Group 4: Beauty and Personal Care - Huaxi Biological (688363.SH) reported a revenue of 3.163 billion yuan for the first three quarters, a year-on-year decrease of 18.36%, primarily due to a strategic contraction in its skin science innovation business [21][22] - The company is optimizing its business structure, with a focus on high-margin pharmaceutical-grade raw materials, which has led to an overall gross margin of 70.68% [22][23] - The company is expected to see a recovery in its skin science business and growth in its raw materials segment, driven by new synthetic biological materials [23]

Investment Rating - The report assigns a "Buy" rating to the company, indicating a strong expected return over the next 6-12 months [5][11]. Core Insights - The company achieved a revenue of 21.986 billion yuan in the first three quarters, representing a year-on-year increase of 11.38%, while the net profit attributable to shareholders was 2.353 billion yuan, down 20.51% year-on-year [1][5]. - The CHC (Consumer Health Care) business shows resilience despite facing pressures from a decline in respiratory disease incidence and adjustments in retail channels. The company has launched several new products under the 999 brand, enhancing its market position [1][2]. - The company is focusing on both internal and external growth strategies, with a clear emphasis on the CHC sector and strategic mergers and acquisitions to enhance operational efficiency and brand value [2][5]. Financial Performance Summary - Revenue projections for the company are as follows: 24.739 billion yuan in 2023, 27.617 billion yuan in 2024, and expected growth to 31.073 billion yuan in 2025, with a growth rate of 36.8% in 2023 and 11.6% in 2024 [3][10]. - The net profit attributable to shareholders is projected to be 2.853 billion yuan in 2023, increasing to 3.368 billion yuan in 2024, with a growth rate of 16.5% in 2023 and 18.1% in 2024 [3][10]. - The earnings per share (EPS) is expected to be 1.71 yuan in 2023, increasing to 2.02 yuan in 2024 [3][10]. Strategic Focus - The company is concentrating on the CHC sector while collaborating with Tian Shili and Kun Yao to enhance management and product pipelines, aiming for a clearer strategic direction and improved performance [2][5]. - The report highlights the company's commitment to innovation in the prescription drug sector, focusing on core areas and exploring diverse opportunities for product acquisition [2][5].

Group 1: Industry Outlook - The retail industry is expected to focus on consumer-centric approaches, returning to brand and academic fields to provide more treatment options for consumers, indicating a sustained growth trend in the retail market [3] - The aging population will drive demand for health services targeting the elderly, with a focus on specialized areas such as DTP and professional pharmacies [3] Group 2: Strategic Planning - The "14th Five-Year" plan has seen industry growth rates decline from approximately 6-7% to around 1%, prompting the company to adopt an "internal + external" growth model, aiming for revenue to double from 136 billion RMB in 2020 to 276 billion RMB by 2024 [4] - The company has achieved a net profit increase from about 1.5 billion RMB to approximately 3.3 billion RMB by 2024, with 2.353 billion RMB completed in the first three quarters of this year [4] Group 3: Financial Performance - The company’s brand value reached 55.864 billion RMB, ranking in the top three of the pharmaceutical industry and making it onto the "2025 Asia Brand 500" list [4] - R&D investment increased from 580 million RMB in 2020 to 950 million RMB in 2024, with 36 products approved during the "14th Five-Year" period [4] Group 4: Inventory and Sales Management - The inventory level for respiratory products is currently normal, with preparations made for the peak demand seasons in Q1 and Q4 [6] - The overall sales expense ratio increased by 3.8 percentage points in the first three quarters of this year, primarily due to the merger with Tian Shi Li [10] Group 5: Future Innovations and Acquisitions - The company is focusing on innovative treatments for heart failure and chronic diseases, particularly in the cardiovascular and diabetes sectors, with significant market potential [8] - Future acquisitions will target brands in the consumer health, medical health, and elderly health sectors, leveraging policy opportunities to enhance innovation and product offerings [9] Group 6: 2025 Business Outlook - The company anticipates that its revenue will exceed the industry average growth rate, aiming for double-digit growth while maintaining stable profits [12]